Últimas noticias sobre HCA Healthcare (NYSE:HCA) Bolsa

HCA Healthcare

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.

HCA Healthcare Inc

HOLDING CO ADMIE IPTO by Holding Co Admie Ipto SA

Holding Co ADMIE (IPTO) SA

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

Health Catalyst Inc

Morgan Stanley analyst Craig Hettenbach maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Equal-Weight and lowers the price target from $406 to $355.

News

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on HCA Healthcare, Lowers Price Target to $355

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 3.84% on an annualized basis producing an average annual return of 15.1%. Currently, HCA Healthcare has a market capitalization of $79.90 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $408.35 today based on a price of $309.60 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734452108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

JP Morgan analyst Benjamin Rossi assumes HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Neutral rating and announces Price Target of $380.

Initiation

JP Morgan Assumes HCA Healthcare at Neutral, Announces Price Target of $380

HCA Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) short percent of float has risen 14.39% since its last report. The company recently reported that it has 2.97 million shares sold short, which is 1.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>HCA Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733258711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for HCA Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing HCA Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, HCA Healthcare's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into HCA Healthcare's Recent Short Interest

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62cd59300ee57b0001a11a55/robert-cox">Goldman Sachs analyst Robert Cox</a> downgraded Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) from Buy to Neutral and maintained the price target of $313. Arthur J. Gallagher shares closed at $304.29 on Friday. <a href="https://www.benzinga.com/quote/AJG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup analyst Keith Horowitz downgraded the rating for M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Buy to Neutral but raised the price target from $220 to $230. M&amp;T Bank shares closed at $221.12 on Friday. <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group analyst Joseph Feldman downgraded Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Outperform to Market Perform and lowered the price target from $102 to $95. Five Below shares closed at $86.92 on Friday. <a href="https://www.benzinga.com/quote/FIVE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Stephen Baxter downgraded the rating for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Equal-Weight to Underweight and slashed the price target from $400 to $320. HCA Healthcare shares closed at $324.93 on Friday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Tina Hou downgraded NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Sell and lowered the price target from $4.8 to $3.9. Nio shares closed at $4.84 on Friday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NIO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1010" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269.png" alt="" class="wp-image-663428" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269.png 1010w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25090521/image-269-768x457.png 768w" sizes="(max-width: 1010px) 100vw, 1010px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

FIVE

This Nio Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Wells Fargo analyst Stephen Baxter downgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Equal-Weight to Underweight and lowers the price target from $400 to $320.

Wells Fargo Downgrades HCA Healthcare to Underweight, Lowers Price Target to $320

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst John Ransom downgraded the rating for HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Market Perform. HCA Healthcare shares closed at $332.24 on Thursday. See how other analysts view this stock.</li>
<li>JMP Securities analyst Matthew Carletti downgraded the rating for Root, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROOT#NASDAQ">ROOT</a>) from Market Outperform to Market Perform. Root shares closed at $109.40 on Thursday. <a href="https://www.benzinga.com/quote/root/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham analyst Mike Matson downgraded TransMedics Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Buy to Hold and maintained the price target of $109. TransMedics shares closed at $79.34 on Thursday. <a href="https://www.benzinga.com/quote/tmdx/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc analyst Steve Barger downgraded the rating for The Timken Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) from Overweight to Sector Weight. Timken shares closed at $75.22 on Thursday. <a href="https://www.benzinga.com/quote/tkr/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities analyst Alex Rygiel downgraded Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) from Buy to Neutral and lowered the price target from $135 to $84. Atkore shares closed at $85.14 on Thursday. <a href="https://www.benzinga.com/quote/atkr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HCA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="558" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22095511/image-247-1024x558.png" alt="" class="wp-image-661076" style="width:678px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22095511/image-247-1024x558.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22095511/image-247-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22095511/image-247-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22095511/image-247.png 1225w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></li>
</ul>

ATKR

ROOT

TMDX

This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Raymond James analyst John Ransom downgrades HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Market Perform.

Raymond James Downgrades HCA Healthcare to Market Perform

Benzinga's options scanner just detected over 8 options trades for HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) summing a total amount of $532,222.
At the same time, our algo caught 6 for a total amount of 637,251.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $315.0 to $335.0 for HCA Healthcare over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for HCA Healthcare's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of HCA Healthcare's whale trades within a strike price range from $315.0 to $335.0 in the last 30 days. 
<h3>HCA Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125645_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.6</td>
<td>$8.4</td>
<td>$8.6</td>
<td>$325.00</td>
<td>$215.7K</td>
<td align="right">86</td>
<td align="right">262</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.6</td>
<td>$9.5</td>
<td>$9.5</td>
<td>$330.00</td>
<td>$139.7K</td>
<td align="right">97</td>
<td align="right">150</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$9.7</td>
<td>$330.00</td>
<td>$95.9K</td>
<td align="right">97</td>
<td align="right">259</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$18.4</td>
<td>$18.3</td>
<td>$18.4</td>
<td>$335.00</td>
<td>$80.9K</td>
<td align="right">2</td>
<td align="right">36</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.8</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$315.00</td>
<td>$72.7K</td>
<td align="right">410</td>
<td align="right">222</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
Following our analysis of the options activities associated with HCA Healthcare, we pivot to a closer look at the company's own performance.
<h3>Where Is HCA Healthcare Standing Right Now?</h3>
<ul>
<li>With a volume of 505,703, the price of HCA is down -1.79% at $329.1. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>What The Experts Say On HCA Healthcare</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $401.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on HCA Healthcare, which currently sits at a price target of $395. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on HCA Healthcare, which currently sits at a price target of $392. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for HCA Healthcare, targeting a price of $420. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on HCA Healthcare, maintaining a target price of $400. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on HCA Healthcare, maintaining a target price of $400. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on HCA Healthcare: Analyzing the Surge in Options Activity

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 17.48%. Currently, HCA Healthcare has a market capitalization of $87.70 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $506.91 today based on a price of $339.83 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731699201_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

Politics

General

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and lowers the price target from $396 to $392.

Barclays Maintains Overweight on HCA Healthcare, Lowers Price Target to $392

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 6.99% on an annualized basis producing an average annual return of 18.14%. Currently, HCA Healthcare has a market capitalization of $90.29 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $531.92 today based on a price of $349.86 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730910641_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Equal-Weight and raises the price target from $395 to $400.

Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $400

Whales with a lot of money to spend have taken a noticeably bearish stance on HCA Healthcare.
Looking at options history for HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 0% of the investors opened trades with bullish expectations and 90% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $248,630 and 5, calls, for a total amount of $223,750.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $360.0 and $375.0 for HCA Healthcare, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for HCA Healthcare options trades today is 235.5 with a total volume of 1,228.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for HCA Healthcare's big money trades within a strike price range of $360.0 to $375.0 over the last 30 days.
<h3>HCA Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730833310_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$17.9</td>
<td>$17.2</td>
<td>$17.5</td>
<td>$365.00</td>
<td>$71.7K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$13.1</td>
<td>$12.7</td>
<td>$12.7</td>
<td>$375.00</td>
<td>$58.4K</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">91</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$13.1</td>
<td>$12.6</td>
<td>$12.6</td>
<td>$375.00</td>
<td>$51.6K</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">178</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.4</td>
<td>$17.0</td>
<td>$17.4</td>
<td>$365.00</td>
<td>$50.4K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">122</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.3</td>
<td>$17.0</td>
<td>$17.3</td>
<td>$365.00</td>
<td>$46.7K</td>
<td style="text-align: right;">31</td>
<td style="text-align: right;">149</td>
</tr>
</tbody>
</table>

<h3>About HCA Healthcare</h3>
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
In light of the recent options history for HCA Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is HCA Healthcare Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 467,360, the HCA's price is down by 0.0%, now at $363.16. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>What The Experts Say On HCA Healthcare</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $426.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for HCA Healthcare, targeting a price of $420. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on HCA Healthcare, which currently sits at a price target of $400. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for HCA Healthcare, targeting a price of $395. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on HCA Healthcare, which currently sits at a price target of $440. 
&#x2A; Reflecting concerns, an analyst from Keybanc lowers its rating to Overweight with a new price target of $475.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest HCA Healthcare options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Looking At HCA Healthcare's Recent Unusual Options Activity

TD Cowen analyst Gary Taylor maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Buy and lowers the price target from $450 to $440.

TD Cowen Maintains Buy on HCA Healthcare, Lowers Price Target to $440

Keybanc analyst Matthew Gillmor maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and lowers the price target from $475 to $420.

Keybanc Maintains Overweight on HCA Healthcare, Lowers Price Target to $420

Oppenheimer analyst Michael Wiederhorn maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Outperform and raises the price target from $390 to $400.

Oppenheimer Maintains Outperform on HCA Healthcare, Raises Price Target to $400

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Friday.
U.S. stocks settled mixed on Friday, with the Nasdaq Composite surging to an all-time high during the session.
Tech stocks provided a boost to the market ahead of their upcoming quarterly earnings. Shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAZN#NASDAQ">AMAZN</a>) settled higher on Friday.
Both the Dow Jones and S&amp;P 500 ended a six-week winning streak, falling around 1% and 2.7%, respectively. The Nasdaq recorded gains for the seventh straight week, gaining nearly 0.2% last week.
Shares of HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) fell around 9% on Friday after the company reported weaker-than-expected third-quarter financial results. Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) shares fell around 4% after the company reported third-quarter earnings.
On the economic data front, the University of Michigan consumer sentiment for the U.S. rose to 70.5 in October compared to a preliminary reading of 68.9. U.S. durable goods orders fell by 0.8% to $284.8 billion in September compared to a revised 0.8% fall in August.
Most sectors on the S&amp;P 500 closed on a negative note, with financials, real estate, and utilities stocks recording the biggest losses on Friday. However, information technology and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 260 points to 42,114.40 on Friday. The S&amp;P 500 fell 0.03% to 5,808.12, while the Nasdaq Composite climbed 0.56% at 18,518.61 during Friday's session.
Investors are awaiting earnings results from ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>), and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 58.9, the index remained in the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 61.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41545103/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

AMAZN

NVDA

Nasdaq Surges To Fresh Highs As Nvidia, Meta And Amazon Register Gains: Fear Index Remains In 'Greed' Zone

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) shares plummeted 25.95% after the company reported <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener">worse-than-expected results</a>. Several analysts also cut the <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) stock tumbled 20.21% after it reported mixed third-quarter results and cut its <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener">FY24 EPS below estimates</a>. Multiple analysts cut the <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) shares dipped 15.97% after the company reported <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Analysts trimmed the <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price target</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock lost 14.71% last week. Several healthcare stocks and hospital operators fell in possible sympathy with HCA Healthcare, which declined on Q3 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock fell 14.33% last week after the company reported <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener">Q3 financial results</a>.</li>
<li>HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock fell 12.51% after reporting <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 financial results</a>. The company expects Hurricane Helene&#8217;s impact to continue in 2025.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock lost 11.48% last week as homebuilding stocks <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener">took a beating</a> due to Hurricane Milton&#8217;s impact.</li>
<li>Carlisle Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) fell 11.45% last week on <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 performance</a>.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock declined 11.34% after it reported <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Some analysts trimmed the <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Comfort Systems USA, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 11.27% after the company reported <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 sales results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

Movers

ICLR

Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2024 Update

The S&P 500 is a treasure trove for investors seeking undervalued stocks offering significant gains. Given this backdrop, it might be wise to scoop up shares of undervalued S&P 500 stocks, Comcast Corp (CMCSA), Elevance Health (ELV), and HCA Healthcare (HCA), offering a chance to capitalize on potential upside. Keep reading… The S&amp;P 500, which serves as a benchmark for the U.S. stock market, often hides undervalued gems overlooked by the market. These stocks trade below Wall Street price targets, offering investors a chance to capitalize on potential upside.
Therefore, I have highlighted three such S&amp;P 500 undervalued stocks, namely, Comcast Corporation (<a href="https://stocknews.com/stock/CMCSA/">CMCSA</a>), Elevance Health, Inc. (<a href="https://stocknews.com/stock/ELV/">ELV</a>), and HCA Healthcare, Inc. (<a href="https://stocknews.com/stock/HCA/">HCA</a>), that have more than 20% potential upside.
Now, one might question how one knows which <a href="https://www.investopedia.com/terms/u/undervalued.asp">stock is undervalued</a>. Undervalued is a financial term referring to a security selling in the market for a price below the investment's true intrinsic value. Key metrics such as price-to-earnings (P/E) and price-to-book (P/B) ratios often signal undervaluation. The stocks trading at a discount to their historical averages or peers could indicate potential upside.
Undervalued stocks are spread across various sectors, including technology, healthcare, and consumer staples. The S&amp;P 500 is one of the most stable Wall Street indexes. The index has an <a href="https://tradethatswing.com/average-historical-stock-market-returns-for-sp-500-5-year-up-to-150-year-averages/">average yearly return of 10.6%</a> over the past 100 years. Furthermore, Goldman Sachs predicts another <a href="https://www.goldmansachs.com/insights/articles/the-s-and-p-500-is-forecast-to-return-10-percent-in-2025">10% return in 2025</a>.
For long-term investors, these undervalued S&amp;P 500 stocks present an opportunity to build positions in fundamentally strong companies that can provide stability and growth potential. Given these favorable trends, let's analyze the fundamental aspects of the CMCSA, ELV, and HCA to understand them better:
Comcast Corporation (<a href="https://stocknews.com/stock/CMCSA/">CMCSA</a>)
CMCSA is a global media and technology company. The company operates through five segments: Residential Connectivity &amp; Platforms; Business Services Connectivity; Media; Studios; and Theme Parks.
On December 11, CMCSA announced that it signed an agreement to acquire Nitel, a U.S. managed services provider, from an international private equity firm in Cinven. This acquisition will help enhance CMCSA's ability to serve enterprise clients and strengthen its capacity in advanced network, cloud, and cybersecurity solutions.
In terms of forward non-GAAP P/E, CMCSA is trading at 9.41x, 32.6% lower than the industry average of 13.96 x. Likewise, the stock's forward EV/EBITDA and Price/Cash flow multiples of 6.49 and 5.68 are 18.4% and 34.1% lower than their respective industry averages of 7.95 and 8.62.
For the nine-month period, which ended on September 30, CMCSA's revenue increased marginally year-over-year to $91.82 billion. The company reported adjusted <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> of $13.24 billion, and its adjusted EPS came in at $3.37 per share, reflecting increases of 1.2% and 7.7% year-over-year, respectively.
The consensus revenue estimate of $31.64 billion for the fiscal fourth quarter (ending December 2024) represents a marginal increase year-over-year. The consensus EPS estimate of $0.87 for the same quarter indicates a 3.1% improvement year-over-year. The company has an excellent earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has surged 5%, closing the last trading session at $40.24.
The 12-month median price target of $49.33 indicates <a href="https://www.tipranks.com/stocks/cmcsa/forecast">a 22.6% upside potential</a> from the last closing price. The price targets range from a low of $42 to a high of $60.
CMCSA's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
CMCSA has a B grade for Value, Stability, and Quality. It is ranked first out of seven stocks in the <a href="https://stocknews.com/category/entertainment-tv-internet-providers/">Entertainment - TV &amp; Internet Providers</a> industry. <a href="https://stocknews.com/stock/CMCSA/">Click here</a> to see the additional ratings for CMCSA (Growth, Momentum, and Sentiment).
Elevance Health, Inc. (<a href="https://stocknews.com/stock/ELV/">ELV</a>)
ELV operates as a health benefits company or health insurer in the United States. It operates through four segments: Health Benefits; CarelonRx; Carelon Services; and Corporate &amp; Other. The company supports consumers, families, and communities across the entire care journey, connecting to the care, support, and resources to lead healthier lives.
On October 15, the company announced a quarterly dividend of $1.63 per share, payable on December 20, 2024. With 13 years of consecutive dividend growth, ELV pays an annual dividend of $6.52, which translates to a yield of 1.69% at the prevailing price levels. Its four-year average dividend yield is 1.13%. The company's dividend payments have grown at a CAGR of 13% over the past three years and a 15.3% CAGR over the past five years.
In terms of forward GAAP P/E, ELV is trading at 14.24x, 51.4% lower than the industry average of 29.30x. Likewise, the stock's forward EV/Sales and Price/Sales multiples of 0.62 and 0.51 are 82.9% and 86.4% lower than the industry averages of 3.65x and 3.75x, respectively.
In the fiscal nine-month period that ended on September 30, 2024, ELV's total revenues increased 2.2% year-over-year to $131.57 billion. The company's adjusted operating gain rose 2.8% from the same period last year to $8.29 billion. Its adjusted net income came in at $6.81 billion, up 4% year-over-year, while its adjusted EPS grew 6% from the year-ago value to $29.14.
Analysts expect ELV's revenue and EPS for the current year (ending December 2024) to be $175.11 billion and $32.97, respectively. For the fiscal year 2025, its revenue is expected to increase 7.1% year-over-year to $187.56 billion, while its EPS is forecasted to settle at $35.26, indicating a 6.9% improvement over the prior year.
Shares of ELV have declined marginally intraday to close the last trading session at $378.39.
Based on Wall Street analysts offering 12-month price targets for ELV in the last three months, <a href="https://www.tipranks.com/stocks/elv/forecast">the average target price is $520.92</a>, indicating a 37.7% change from the last price.
ELV's POWR Ratings reflect this robust outlook. It has an overall rating of B, which equates to a Buy in our proprietary rating system.
It has a B grade for Value. The stock is ranked #5 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry. <a href="https://stocknews.com/stock/ELV/">Click here</a> to access the additional ELV ratings (Growth, Momentum, Stability, Sentiment, and Quality).
HCA Healthcare, Inc. (<a href="https://stocknews.com/stock/HCA/">HCA</a>)
HCA is a healthcare services company that owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals offering medical and surgical services, including inpatient care, intensive care, diagnostic, emergency, and outpatient services.
On October 25, buoyed by strong financial performance, the company declared a quarterly dividend of $0.66, payable on December 27, 2024. HCA pays an annual dividend of $2.64, which translates to a yield of 0.84% at the prevailing price levels. Its four-year average dividend yield is 0.73%. Moreover, the company's dividend payments have grown at a CAGR of 11.2% over the past three years.
In terms of forward non-GAAP P/E, HCA is trading at 14.36x, which is 31.8% lower than the industry average of 21.05x. The stock's forward EV/EBITDA ratio of 8.99x is 32.1% below the industry average of 13.25x. Also, its forward Price/Sales multiple of 1.13 compares to the industry average of 3.75x.
HCA's revenues for the third quarter (ended September 30, 2024) increased 7.9% year-over-year to $17.49 billion. Its adjusted EBITDA is $3.27 billion, indicating a 13.4% growth from the prior year's quarter. The company's attributable net income came in at $1.27 billion, up 17.7% year-over-year. Also, its adjusted net income attributable grew 25.3% from the same period last year to $4.90 per share.
Street expects HCA's revenue for the fiscal fourth quarter (ending December 2024) to increase 5.4% year-over-year to $18.23 billion. Its EPS for the same period is expected to register a 4.4% growth from the prior year, settling at $6.16. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters, which is promising.
The stock has gained 19.1% over the past year to close the last trading session at $311.99.
Based on Wall Street analysts offering 12-month price targets for HCA in the last three months, <a href="https://www.tipranks.com/stocks/hca/forecast">the average target price is $408.31</a>, indicating a 30.9% change from the last price, with a high forecast of $460 and a low forecast of $320.
It's no surprise that HCA has an overall rating of B, equating to a Buy in our POWR Ratings system. It has a B grade for Value, Stability, and Quality. Out of 10 stocks in the B-rated <a href="https://stocknews.com/category/hospitals/">Medical - Hospitals</a> industry, HCA is ranked #3.
Beyond what is stated above, we've also rated HCA for Growth, Momentum, and Sentiment. Get all HCA ratings <a href="https://stocknews.com/stock/HCA/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
CMCSA shares were trading at $39.89 per share on Friday afternoon, down $0.35 (-0.87%). Year-to-date, CMCSA has declined -6.30%, versus a 28.06% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/cmcsa-elv-hca-3-sp-500-stocks-undervalued-by-wall-street-price-targets/>3 S&P 500 Stocks Undervalued by Wall Street Price Targets</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 S&P 500 Stocks Undervalued by Wall Street Price Targets

JPMorgan assumed coverage of HCA Healthcare (HCA) with a Neutral rating and $380 price target The firm believes favorable trends across sales and e...

HCA Healthcare assumed with a Neutral at JPMorgan

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on HCA Healthcare (HCA – Research Report), with a price t...

Morgan Stanley Reaffirms Their Hold Rating on HCA Healthcare (HCA)

IHF: Healthcare Dashboard For December

High-beta stocks are perfect for aggressive investors, amplifying profits during bull markets and delivering exceptional returns in favorable economic conditions. Therefore, Spotify Technology (SPOT), HCA Healthcare (HCA), and DoorDash (DASH) could be smart buying opportunities right now. Read on to learn more... High-beta stocks often shine during bull markets, delivering exceptional returns to investors ready to embrace risk. These stocks, typically from emerging or high-growth sectors, are ideal for aggressive growth strategies. With their volatility and rapid price swings, they appeal to those seeking short-term gains.
Hence, aggressive investors might consider high-beta picks like Spotify Technology S.A. (<a href="https://stocknews.com/stock/SPOT/">SPOT</a>), HCA Healthcare, Inc. (<a href="https://stocknews.com/stock/HCA/">HCA</a>), and DoorDash, Inc. (<a href="https://stocknews.com/stock/DASH/">DASH</a>), all boasting a 60-month beta above 1.50.
Economic activity has seen modest expansion across most regions since early October, with moderate expectations across sectors. Despite persistent inflation, markets are anticipating a <a href="https://www.reuters.com/markets/us/us-economy-grew-slightly-recent-weeks-fed-survey-says-2024-12-04/">quarter-point rate cut</a>, with current rates at 4.50%-4.75% and further reductions expected to bolster the economy. Businesses remain optimistic about improved demand in the near term, despite ongoing challenges.
Meanwhile, the current <a href="https://www.marketwatch.com/story/the-bull-market-is-nearing-its-second-birthday-heres-why-it-will-likely-continue-52738815">bull market</a> offers favorable conditions for investors. Historically, bull markets lasting two years often extend into the third year, though risks like inflation and geopolitical tensions may influence future performance. For aggressive investors, high-beta stocks, which react significantly to market movements and amplify profits during economic booms, present an attractive opportunity.
With these favorable trends in mind this December, let's analyze the fundamental aspects of the three high-beta picks.
Spotify Technology S.A. (<a href="https://stocknews.com/stock/SPOT/">SPOT</a>)
Based in Luxembourg, Luxembourg, SPOT and its subsidiaries provide audio streaming services worldwide. They operate through two segments: Premium and Ad-Supported.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/a/assetturnover.asp">asset turnover ratio</a>, SPOT's 1.66x is 236.4% higher than the 0.49x industry average. Also, its trailing-12-month Return on Common Equity and Return on Total Assets of 20.70% and 6.64% are 387.4% and 284% higher than the industry averages of 4.25% and 1.673%, respectively.
For the third quarter ending September 30, 2024, SPOT's revenue increased by 18.8% year-over-year to €3.99 billion ($4.19 billion). The company's gross profit rose 40.1% from the prior-year period to €1.24 billion ($1.30 billion). During the same period, its net income attributable to owners of the parent was €300 million ($315.25 million) or €1.45 per share, up 361.5% and 339.4% year-over-year, respectively.
For the quarter ending December 31, 2024, SPOT's revenue is expected to increase 9.9% year-over-year to $4.34 billion. Its EPS for the quarter ending March 31, 2025, is expected to increase 81.3% year-over-year to $1.88. SPOT's stock has gained 167.4% year-to-date to close the last trading session at $502.38. Its 60-month beta is 1.61.
SPOT's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has an A grade for Growth and a B for Quality. It is ranked #2 out of 4 stocks in the <a href="https://stocknews.com/category/entertainment-radio/">Entertainment - Radio</a> industry. Beyond what we stated above, we have also rated SPOT for Value, Momentum, Stability, and Sentiment. Get all ratings of SPOT <a href="https://stocknews.com/stock/SPOT/">here</a>.
HCA Healthcare, Inc. (<a href="https://stocknews.com/stock/HCA/">HCA</a>)
HCA and its subsidiaries, provide healthcare services in the United States. It operates general and acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
In terms of the trailing-12-month EBITDA margin, HCA's 19.75% is 245.9% higher than the 5.71% industry average. Likewise, its 5.96% trailing-12-month levered FCF margin is 172.3% higher than the 2.19% industry average. Furthermore, its 1.22x trailing-12-month asset turnover ratio is 193.9% higher than the 0.42x industry average.
During the fiscal third quarter that ended September 30, 2024, HCA's revenues increased 7.9% year-over-year to $17.49 billion. Its adjusted net income attributable to HCA was $1.27 billion, up 18.1% from the prior-year quarter, while its adjusted earnings per share rose 25.3% year-over-year to $4.90. Additionally, its adjusted EBITDA grew to $3.27 billion from the year-ago value.
Street expects HCA's EPS and revenue for the quarter ending December 31, 2024, to increase 4.4% and 5.4% year-over-year to $6.16 and $18.23 billion, respectively. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 26% to close the last trading session at $324.09. Its 60-month beta is 1.64.
It's no surprise that HCA has an overall rating of B, which translates to a Buy in our proprietary POWR Ratings system.
It has a B grade for Value, Stability, and Quality. Within the B-rated <a href="https://stocknews.com/category/hospitals/">Medical - Hospitals</a> industry, it is ranked #3 out of 10 stocks. To access additional grades for HCA's Growth, Momentum, and Sentiment ratings, <a href="https://stocknews.com/stock/HCA/">click here</a>.
DoorDash, Inc. (<a href="https://stocknews.com/stock/DASH/">DASH</a>)
DASH is a global platform that links merchants, consumers, and contractors, offering marketplaces (DoorDash, Wolt), membership products (DashPass), delivery fulfillment (Drive), and e-commerce tools (Storefront, Bbot) to support order fulfillment, customer acquisition, and digital ordering solutions.
On November 26, 2024, DASH Canada and Walmart Canada announced a nationwide partnership, enabling on-demand delivery of groceries and general merchandise from over 300 Walmart Supercentres across 10 provinces. The collaboration provides Canadians with affordable, convenient shopping options through DASH's app and website.
On November 18, 2024, DASH announced new holiday features, including a redesigned shopping experience, gifting options with personalized notes, and discounts on DashPass for SNAP/EBT recipients. The platform also introduced bundled multi-store orders, holiday deals, and exclusive partnerships to simplify and save time on shopping and gifting this season.
In terms of the trailing-12-month gross profit margin, DASH's 48.78% is 28.3% higher than the 38.04% industry average. Also, its 18.31% trailing-12-month levered FCF margin is 296.3% higher than the 4.62% industry average.
In the fiscal third quarter that ended on September 30, 2024, DASH's revenues increased 25% year-over-year to $2.71 billion. Its income from operations was $107 million, compared to a loss from operations of $108 million in the year-ago quarter.
Similarly, its net income attributable to DASH and net income per share attributable to Class A and Class B stockholders stood at $162 million and $0.38, respectively, compared to a net loss and net loss per share of $73 million and $0.19 in the year-ago quarter.
Analysts expect DASH's revenue for the quarter ending December 31, 2024, to increase 23.1% year-over-year to $2.84 billion. Its EPS for the same quarter is expected to grow 122.1% year-over-year to $0.93. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, DASH's stock has gained 79.8% to close the last trading session at $176.88. Its 60-month beta is 1.70.
DASH's POWR Ratings reflect strong prospects. It has an overall rating of B, translating to a Buy in our proprietary rating system.
It has an A grade for Growth and a B for Sentiment and Quality. It is ranked #8 out of 24 stocks in the <a href="https://stocknews.com/category/internet-services/">Internet - Services</a> industry. To see DASH's Value, Momentum, and Stability ratings, <a href="https://stocknews.com/stock/DASH/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
SPOT shares were trading at $490.51 per share on Thursday afternoon, down $11.87 (-2.36%). Year-to-date, SPOT has gained 161.03%, versus a 29.21% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/spot-hca-dash-3-high-beta-stocks-for-aggressive-investors/>3 High-Beta Stocks for Aggressive Investors</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Beta Stocks for Aggressive Investors

U.S. healthcare spending climbs 7.5% in 2023

HCA Healthcare (HCA) announced that Wendy Warren, a more than 10-year veteran of HCA Healthcare, has been appointed senior vice president and chief...

HCA Healthcare chief ethics, compliance officer Kathi Whalen to retire

Materials, software stocks are best poised for H1 outperformance: Goldman Sachs

AAPL

ACHC

ADBE

ADPT

AKAM

AMZN

AVGO

BBIO

BIIB

BMRN

CBRE

CMCSA

CNMD

COLL

CRWD

CTSH

DASH

DDOG

DLTR

EPAM

EVRG

EWTX

FERG

FICO

FLUT

GEHC

HRMY

INBX

INCY

ISRG

LNTH

MSFT

NAMS

NFLX

ORIC

PEPG

PHVS

PLTR

PODD

ROIV

RPRX

SGRY

SPOT

TEAM

TMUS

TRVI

VEEV

VICI

VKTX

VTRS

WDAY

WELL

Press Releases

HCA Healthcare Presents 2024 Awards of Distinction

HCA Healthcare, Inc. 3rd Quarter 2024 Earnings Conference Call

HCA Healthcare to Donate $1 Million Towards Hurricane Helene Disaster Relief Efforts in North Carolina

HCA Healthcare, Inc. to Present at November Healthcare Conferences

HCA Healthcare to Host Sixth Annual "Crush the Crisis" National Prescription Drug Take Back Day

HCA Healthcare Reports Third Quarter 2024 Results

HCA Healthcare Named a Best Employer for Veterans by Military Times for Fifth Consecutive Year

The Frist Foundation Gives $1 Million to the HCA Healthcare Hope Fund in Support of HCA Healthcare Colleagues Impacted by Hurricanes Helene and Milton

HCA Healthcare Collects Record-Breaking 21,137 Pounds of Medication During Sixth Annual "Crush the Crisis"

HCA Healthcare Names Wendy Warren as Senior Vice President and Chief Ethics and Compliance Officer

Comments

HCA Healthcare

Noticias

Últimas noticias sobre HCA Healthcare (NYSE:HCA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL